Fishnet NewMedia http://www.ahoy.com/ Fishnet NewMedia is a Solutions and Hosting provider specializing in Web and Internet Technology. en-us Fishnet NewMedia logo http://www.ahoy.com/images/Nav_Logo.gif http://www.ahoy.com/ 200 66 Fishnet NewMedia logo Ultragenyx Appoints Eric Yuen, MD as Chief Medical Officer and Senior Vice President Ultragenyx Pharmaceutical Inc., a biotechnology company focused on the development of treatments for rare and ultra-rare genetic disorders, today announced it has appointed Eric Yuen, MD as its Chief Medical Officer and Senior Vice President. In this new role, Dr. Yuen will provide leadership and direction to Clinical Operations, Clinical Affairs, Clinical Sciences, Data Management/Biometrics, and Drug Safety. He will report to Dr. Emil Kakkis, CEO, and will serve on the Senior Management Team. http://www.fidelitybiosciences.com/news/news_detail.cgi/212/0 Wed, 01 May 2013 05:13:00 GMT News Tetraphase Pharmaceuticals Announces Exercise of Underwriters' Option to Purchase Additional Shares in its Initial Public Offering Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) today announced that the underwriters for its initial public offering have exercised their over-allotment option and purchased an additional 797,792 shares in the offering. The sale of the additional shares, together with the shares sold at the initial closing of the offering, brings the total number of shares sold in the offering to 11,512,078 resulting in aggregate proceeds of $80.6 million, before underwriting discounts, commissions and expenses. Tetraphase's common stock is listed on the NASDAQ Global Market under the symbol "TTPH." All of the shares in the offering were offered by Tetraphase Pharmaceuticals. http://www.fidelitybiosciences.com/news/news_detail.cgi/211/0 Fri, 12 Apr 2013 05:13:00 GMT News Ultragenyx Initiates Novel Disease Monitoring Program for Hereditary Inclusion Body Myopathy Ultragenyx Pharmaceutical Inc. today announced the launch of a unique Disease Monitoring Program (DMP) for Hereditary Inclusion Body Myopathy (HIBM), also known as GNE Myopathy. The goal of the HIBM-DMP is to improve the body of knowledge about this rare disease and its typical course. This novel program is being conducted in partnership with the University of Newcastle's TREAT-NMD organization, a global neuromuscular physician network. http://www.fidelitybiosciences.com/news/news_detail.cgi/210/0 Mon, 08 Apr 2013 05:13:00 GMT News